Tyra Biosciences, Inc. Share Price
TYRATyra Biosciences, Inc. Stock Performance
Open $30.38 | Prev. Close $31.28 | Circuit Range N/A |
Day Range $29.69 - $31.38 | Year Range $6.42 - $32.42 | Volume 28,552 |
Average Traded $30.80 |
Tyra Biosciences, Inc. Share Price Chart
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Tyra Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Feb-26 | $30.38 | $31.02 | +5.12% |
05-Feb-26 | $30.32 | $29.51 | -4.03% |
04-Feb-26 | $30.89 | $30.75 | -1.51% |
03-Feb-26 | $31.50 | $31.22 | +0.74% |
02-Feb-26 | $30.68 | $30.99 | +0.28% |
30-Jan-26 | $31.71 | $30.91 | -4.26% |
29-Jan-26 | $31.12 | $32.28 | +3.89% |